| Kathryn Marie Malatestinic, ATC | |
|
1500 Lexington Blvd, Bethel, CT 06801-1338 | |
| (203) 240-7122 | |
| Not Available |
| Full Name | Kathryn Marie Malatestinic |
|---|---|
| Gender | Female |
| Speciality | Specialist/technologist - Athletic Trainer |
| Location | 1500 Lexington Blvd, Bethel, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881184109 | NPI | - | NPPES |
| 22 | Other | RESPIRATORY, REHABILITATIVE & RESTORATIVE SERVICE PROVIDERS |
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn Marie Malatestinic, ATC 2011 Village View Cir Apt 202, Belmont, NC 28012-3199 Ph: (203) 240-7122 | Kathryn Marie Malatestinic, ATC 1500 Lexington Blvd, Bethel, CT 06801-1338 Ph: (203) 240-7122 |
News Archive
Advances in brain imaging can identify a greater number of stroke patients who can receive therapy later than previously believed, according to a new study.
Dyadic International, Inc. announced today an agreement to resolve the consolidated stockholder class action lawsuit against Dyadic and certain of its current and former officers and directors which was initially filed in October 2007.
Using exquisitely detailed maps of molecular shapes and the electrical charges surrounding them, researchers at National Jewish Health have discovered how the metal beryllium triggers a deadly immune response in the lungs.
Recurrence of breast cancer in the same area as the original tumour remains the strongest, independent prognostic factor for subsequent metastasis and death, even for patients who have been free of disease for a very long time, according to research presented today (Wednesday) at the seventh European Breast Cancer Conference (EBCC7).
An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms.
› Verified 2 days ago